Compare BKSY & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKSY | TSHA |
|---|---|---|
| Founded | 2013 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.0M | 1.7B |
| IPO Year | 2019 | 2020 |
| Metric | BKSY | TSHA |
|---|---|---|
| Price | $21.70 | $5.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $28.50 | $11.63 |
| AVG Volume (30 Days) | 813.8K | ★ 2.0M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 21.72 | 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $27.03 | N/A |
| Revenue Next Year | $29.21 | $1,152.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $12.41 | $2.72 |
| 52 Week High | $52.88 | $7.30 |
| Indicator | BKSY | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 42.40 | 33.36 |
| Support Level | $20.06 | $4.37 |
| Resistance Level | $24.35 | $5.07 |
| Average True Range (ATR) | 1.35 | 0.25 |
| MACD | 0.11 | -0.04 |
| Stochastic Oscillator | 40.63 | 10.85 |
BlackSky Technology Inc is a space-based technology company that delivers real-time imagery, analytics and high-frequency monitoring of the worlds critical and strategic locations, economic assets, and events. By taking a software-first technology approach, Company is delivering real-time space-based intelligence at disruptive speed, scale and economics. Companies single operating and reportable segment, provided space-based intelligence products and services through three integrated revenue streams-space-based intelligence & AI services, mission solutions, and technology programs. Geographically, the company operates in United States and Rest of world.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.